IONS - Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential | Benzinga
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated amyloidosis in adults (hATTR-PN or ATTRv-PN).
Wainua is the only approved medicine for ATTRv-PN that can be self-administered via an auto-injector.
William Blair sees potential for greater than $700 million in peak Wainua sales in ATTR-PN alone, which will be a significant value driver.
Ionis is also positioned to benefit from Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) HELIOS B cardiovascular outcomes trial readout in 1H ...